

**REMARKS**

The claims are 49-57, 59-67, 70, 71, and 92-107. Claims 1-48, 58, 68, 69, and 72-91 have been cancelled without prejudice or disclaimer. Claim 49 has been amended to recite that, in the compounds of Formula I, W<sup>1</sup> is selected from C<sub>3</sub>-C<sub>8</sub> cycloalkyl, aryl and Het. Claims 66, 67 and 105 have been amended in accordance with claim 49. Claims 102, 105 and 106 were amended to correct a typographical error. Claim 106 was also amended to remove the duplicate recitations of several compounds. No new matter has been added,

Claims 65, 67, 70, 92-104, 106, and 107 were withdrawn by the Examiner from consideration. Applicants respectfully request re-consideration of these claims.

Claims 49-66, 71 and 72 were rejected under 35 U.S.C. 112, second paragraph. The Examiner noted irregularities in the proviso and definition of "Het" in claim 49. The proviso of claim 49 has been reviewed and amended in accordance with the substituent definitions of claim 49. The definition of "Het" has been amended in accordance with the Examiner's suggestion at page 8 of the office action.

Claims 55 and 66 were rejected as allegedly indefinite because the Examiner considers the limitation, "or X an adjacent R<sup>3</sup>, taken together with the atoms to which they are bonded, form an alkylenedioxy moiety," to lack antecedent basis in claim 49. Applicants wish to direct the Examiner's attention to claim 49, where in lines 6-7 (below the structure), this recitation is provided.

Claims 49-52, 54, 55, 57, 59, 62, 64, and 71 were rejected under 35 U.S.C. 102(b) as allegedly anticipated by U.S. 4,220,645 (Chibret) and claims 49-62, 66, and 71 were rejected under 35 U.S.C. 102(b) as allegedly anticipated by WO 00/18723 (Sikorski et al.). Claim 53 was rejected under 35 U.S.C. 103(a) as allegedly unpatentable over U.S. 4,220,645 (Chibret).


Applicants respectfully submit that the amendments to claim 49 render each of these rejections moot; neither Chibret nor Sikorski disclose or suggest compounds that may be defined by Formula I where W<sup>1</sup> is a C<sub>3</sub>-C<sub>8</sub> cycloalkyl, aryl or Het group.

In view of the foregoing remarks, Applicants respectfully submit that the subject application is in condition for allowance. Applicants believe that they have addressed each of the Examiner's concerns and met each of the objections. If the Examiner has any remaining objections or concerns, the Examiner is respectfully requested to contact Applicants' undersigned attorney to resolve such issues and advance the case to issue.

U.S. Application No.: 10/508,894  
Group Art Unit No.: 1624

Authorization is hereby provided to charge Deposit Account No. 19-2570 any fees under 37 C.F.R. §1.16 or §1.17 that may be required for entry and consideration of these papers.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Kathryn L. Sieburth', written in a cursive style.

Kathryn L. Sieburth  
Attorney for Applicants  
Registration No. 40,072

GLAXOSMITHKLINE  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5012  
Facsimile (610) 270-5090  
N:\KLS\Cases\IP51328\Natl Stage\ROA\_7\_19\_07.doc